(AOF) – Mauna Kea Technologies announced second-quarter 2023 revenue growth of 77% year-on-year, supported by sales in the United States and by licensing revenue from the joint venture with Tasly Pharmaceutical. Inventor of Cellvizio, the multidisciplinary probe and needle laser confocal endomicroscopy (p/nCLE) platform reports accelerating growth to 50% in the field of PU (“pay-per-use”), “benefiting from increased use and new users” and continued buoyant activity in Clinical Development”.
“Following on from the very good results of the first quarter, we are very satisfied with our commercial performance in the second quarter, supported by a remarkable momentum in sales in the United States for both systems and consumables, and also our PPU (pay-per-use) program, despite the persistent problems with the supply of fluorescein” declared Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
